Pulmonary Hypertension Drug Market Report

China Pulmonary Hypertension Drug Industry Market Research Report 2023-2029

  • POSTDATE：Oct 12, 2023
  • PAGES：149
  • REPORT CODE：GMM1848600
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • This report elaborates on the current development of the Pulmonary Hypertension Drug industry thoroughly based on the international market dynamics and China's market situation.

    For a start, the report provides an in-depth analysis of the current market situation through three different aspects - by region, by type and by application, which includes market distribution of different types and applications, import and export analysis of major regions, development trends of different types of products in each region, market opportunities and market restrains of different applications.

    Secondly, this report lists the major players in the industry, displaying their market positions and strengths and weaknesses of their products, picturing the current competitive situation of the whole market. 

    Last but not least, the report analyzes and predicts the investment prospects and risks in the industry on the basis of industry data, combined with experts' opinions and suggestions.

    By Player:

    • Boehringer Ingelheim GmbH

    • Merck & Co, Inc

    • GlaxoSmithKline plc

    • Teva Pharmaceutical Industries Ltd

    • AstraZeneca plc

    • Vectura Group plc

    • Pfizer Inc

    • F Hoffmann-La Roche AG

    • Abbott Laboratories

    By Type:

    • Endothelin Receptor Antagonists

    • Phosphodiesterase-5 Inhibitors

    • Prostacyclin and Prostacyclin Analogs

    • Soluble Guanylate Cyclase Stimulators

    By Application:

    • Early-stage Drug Candidates (Phase I & Phase II)

    • Late-stage Drug Candidates (Phase III & Registration Phase)

    By Research Region:

    • North China

    • Central China

    • South China

    • East China

    • Northeast China

    • Southwest China

    • Northwest China

  • TABLE OF CONTENT

    Chapter 1 China Pulmonary Hypertension Drug Market Overview 2018-2029

    • 1.1 China Pulmonary Hypertension Drug Industry Development Overview

    • 1.2 China Pulmonary Hypertension Drug Industry Development History

    • 1.3 China Pulmonary Hypertension Drug Industry Market Size (2018-2029)

    • 1.4 China Pulmonary Hypertension Drug Market Analysis by Type from Production Side

      • 1.4.1 China Pulmonary Hypertension Drug Production Volume, Production Value and Growth Rate of Endothelin Receptor Antagonists (2018-2029)

      • 1.4.2 China Pulmonary Hypertension Drug Production Volume, Production Value and Growth Rate of Phosphodiesterase-5 Inhibitors (2018-2029)

      • 1.4.3 China Pulmonary Hypertension Drug Production Volume, Production Value and Growth Rate of Prostacyclin and Prostacyclin Analogs (2018-2029)

      • 1.4.4 China Pulmonary Hypertension Drug Production Volume, Production Value and Growth Rate of Soluble Guanylate Cyclase Stimulators (2018-2029)

    • 1.5 China Pulmonary Hypertension Drug Market Analysis by Application from Consumption End

      • 1.5.1 China Pulmonary Hypertension Drug Sales Volume, Sales Value and Growth Rate of Early-stage Drug Candidates (Phase I & Phase II) (2018-2029)

      • 1.5.2 China Pulmonary Hypertension Drug Sales Volume, Sales Value and Growth Rate of Late-stage Drug Candidates (Phase III & Registration Phase) (2018-2029)

    • 1.6 China Pulmonary Hypertension Drug Market Analysis by Region

      • 1.6.1 North China Pulmonary Hypertension Drug Market Size and Growth Rate from 2018-2029

      • 1.6.2 Central China Pulmonary Hypertension Drug Market Size and Growth Rate from 2018-2029

      • 1.6.3 South China Pulmonary Hypertension Drug Market Size and Growth Rate from 2018-2029

      • 1.6.4 East China Pulmonary Hypertension Drug Market Size and Growth Rate from 2018-2029

      • 1.6.5 Northeast China Pulmonary Hypertension Drug Market Size and Growth Rate from 2018-2029

      • 1.6.6 Southwest China Pulmonary Hypertension Drug Market Size and Growth Rate from 2018-2029

      • 1.6.7 Northwest China Pulmonary Hypertension Drug Market Size and Growth Rate from 2018-2029

    Chapter 2 China Pulmonary Hypertension Drug Industry Development Environment

    • 2.1 Industry Development Environment Analysis

      • 2.1.1 Industry Technological Progress Analysis

      • 2.1.2 Industrial Organizational Innovation Analysis

      • 2.1.3 Changes in Social Habits

      • 2.1.4 Alterations in Government Policies

      • 2.1.5 Impact of Economic Globalization

    • 2.2 Domestic and Foreign Industry Competition Analysis

      • 2.2.1 Comparative Analysis on Pulmonary Hypertension Drug Market Status and Competition at home and abroad in 2023

      • 2.2.2 China Pulmonary Hypertension Drug Market Status and Competition Analysis in 2023

      • 2.2.3 China Pulmonary Hypertension Drug Market Concentration Analysis in 2023

    • 2.3 Problems and Countermeasures in the development of China Pulmonary Hypertension Drug Industry

      • 2.3.1 Industry Development Constraints

      • 2.3.2 Industry Development Considerations

      • 2.3.3 Suggestions on Industry Development Measures

      • 2.3.4 Development Strategies for SMEs

    • 2.4 Influence of COVID-19 Outbreak on Pulmonary Hypertension Drug Industry Development

    Chapter 3 Pulmonary Hypertension DrugIndustry Chain Analysis

    • 3.1 Pulmonary Hypertension Drug Industry Chain

    • 3.2 Pulmonary Hypertension Drug Upstream Industry Analysis

      • 3.2.1 Upstream Industry Development Status

      • 3.2.2 Upstream Industry Development Forecast

      • 3.2.3 Impact of Upstream Industry on the Pulmonary Hypertension Drug Market

    • 3.3 Pulmonary Hypertension Drug Downstream Industry Analysis

      • 3.3.1 Downstream Industry Development Status

      • 3.3.2 Downstream Industry Development Forecast

      • 3.3.3 Impact of Downstream Industry on the Pulmonary Hypertension Drug Market

    Chapter 4 China Pulmonary Hypertension Drug Market, by Type

    • 4.1 China Pulmonary Hypertension Drug Market Trend, by Type

    • 4.2 Product Types of Major Suppliers

    • 4.3 Competitive Landscape of Major Types

    • 4.4 China Pulmonary Hypertension Drug Total Production Volume and Growth Rate from Production Side

    • 4.5 China Pulmonary Hypertension Drug Production Volume and Growth Rate, by Type

      • 4.5.1 China Pulmonary Hypertension Drug Production Volume and Growth Rate of Endothelin Receptor Antagonists

      • 4.5.2 China Pulmonary Hypertension Drug Production Volume and Growth Rate of Phosphodiesterase-5 Inhibitors

      • 4.5.3 China Pulmonary Hypertension Drug Production Volume and Growth Rate of Prostacyclin and Prostacyclin Analogs

      • 4.5.4 China Pulmonary Hypertension Drug Production Volume and Growth Rate of Soluble Guanylate Cyclase Stimulators

    Chapter 5 China Pulmonary Hypertension Drug Market, by Application

    • 5.1 Downstream Market Overview

    • 5.2 Competitive Landscape of Major Applications

    • 5.3 Market Potential Analysis, by Application

    • 5.4 China Pulmonary Hypertension Drug Total Market Size and Growth Rate from Consumption End

    • 5.5 China Pulmonary Hypertension Drug Market Size and Growth Rate, by Application

      • 5.5.1 China Pulmonary Hypertension Drug Market Size and Growth Rate of Early-stage Drug Candidates (Phase I & Phase II)

      • 5.5.2 China Pulmonary Hypertension Drug Market Size and Growth Rate of Late-stage Drug Candidates (Phase III & Registration Phase)

    Chapter 6 China Pulmonary Hypertension Drug Market, by Region

    • 6.1 China Pulmonary Hypertension Drug Production Volume and Production Value, by Region

    • 6.2 China Pulmonary Hypertension Drug Sales Volume and Sales Value, by Region

    Chapter 7 North China Pulmonary Hypertension Drug Market Analysis

    • 7.1 North China Pulmonary Hypertension Drug Market, by Type

    • 7.2 North China Pulmonary Hypertension Drug Market, by Application

    Chapter 8 Central China Pulmonary Hypertension Drug Market Analysis

    • 8.1 Central China Pulmonary Hypertension Drug Market, by Type

    • 8.2 Central China Pulmonary Hypertension Drug Market, by Application

    Chapter 9 South China Pulmonary Hypertension Drug Market Analysis

    • 9.1 South China Pulmonary Hypertension Drug Market, by Type

    • 9.2 South China Pulmonary Hypertension Drug Market, by Application

    Chapter 10 East China Pulmonary Hypertension Drug Market Analysis

    • 10.1 East China Pulmonary Hypertension Drug Market, by Type

    • 10.2 East China Pulmonary Hypertension Drug Market, by Application

    Chapter 11 Northeast China Pulmonary Hypertension Drug Market Analysis

    • 11.1 Northeast China Pulmonary Hypertension Drug Market, by Type

    • 11.2 Northeast China Pulmonary Hypertension Drug Market, by Application

    Chapter 12 Southwest China Pulmonary Hypertension Drug Market Analysis

    • 12.1 Southwest China Pulmonary Hypertension Drug Market, by Type

    • 12.2 Southwest China Pulmonary Hypertension Drug Market, by Application

    Chapter 13 Northwest China Pulmonary Hypertension Drug Market Analysis

    • 13.1 Northwest China Pulmonary Hypertension Drug Market, by Type

    • 13.2 Northwest China Pulmonary Hypertension Drug Market, by Application

    Chapter 14 Company Profiles

      • 14.1 Boehringer Ingelheim GmbH

        • 14.1.1 Boehringer Ingelheim GmbH Company Profile

        • 14.1.2 Boehringer Ingelheim GmbH Pulmonary Hypertension Drug Market Performance

        • 14.1.3 Product&Service Introduction

      • 14.2 Merck & Co, Inc

        • 14.2.1 Merck & Co, Inc Company Profile

        • 14.2.2 Merck & Co, Inc Pulmonary Hypertension Drug Market Performance

        • 14.2.3 Product&Service Introduction

      • 14.3 GlaxoSmithKline plc

        • 14.3.1 GlaxoSmithKline plc Company Profile

        • 14.3.2 GlaxoSmithKline plc Pulmonary Hypertension Drug Market Performance

        • 14.3.3 Product&Service Introduction

      • 14.4 Teva Pharmaceutical Industries Ltd

        • 14.4.1 Teva Pharmaceutical Industries Ltd Company Profile

        • 14.4.2 Teva Pharmaceutical Industries Ltd Pulmonary Hypertension Drug Market Performance

        • 14.4.3 Product&Service Introduction

      • 14.5 AstraZeneca plc

        • 14.5.1 AstraZeneca plc Company Profile

        • 14.5.2 AstraZeneca plc Pulmonary Hypertension Drug Market Performance

        • 14.5.3 Product&Service Introduction

      • 14.6 Vectura Group plc

        • 14.6.1 Vectura Group plc Company Profile

        • 14.6.2 Vectura Group plc Pulmonary Hypertension Drug Market Performance

        • 14.6.3 Product&Service Introduction

      • 14.7 Pfizer Inc

        • 14.7.1 Pfizer Inc Company Profile

        • 14.7.2 Pfizer Inc Pulmonary Hypertension Drug Market Performance

        • 14.7.3 Product&Service Introduction

      • 14.8 F Hoffmann-La Roche AG

        • 14.8.1 F Hoffmann-La Roche AG Company Profile

        • 14.8.2 F Hoffmann-La Roche AG Pulmonary Hypertension Drug Market Performance

        • 14.8.3 Product&Service Introduction

      • 14.9 Abbott Laboratories

        • 14.9.1 Abbott Laboratories Company Profile

        • 14.9.2 Abbott Laboratories Pulmonary Hypertension Drug Market Performance

        • 14.9.3 Product&Service Introduction

    Chapter 15 Research Conclusions and Investment Suggestions

    • 15.1 Pulmonary Hypertension Drug Industry Research Conclusions

    • 15.2 Pulmonary Hypertension Drug Industry Investment Suggestions

      • 15.2.1 Suggestions on Industry Development Strategy

      • 15.2.2 Suggestions on Industry Investment Direction

      • 15.2.3 Suggestions on Industry Investment Strategy


    List of Tables and Figures

    • Figure China Pulmonary Hypertension Drug Industry Market Size (2018-2029)

    • Figure China Pulmonary Hypertension Drug Production Volume, Production Value and Growth Rate of Endothelin Receptor Antagonists (2018-2029)

    • Figure China Pulmonary Hypertension Drug Production Volume, Production Value and Growth Rate of Phosphodiesterase-5 Inhibitors (2018-2029)

    • Figure China Pulmonary Hypertension Drug Production Volume, Production Value and Growth Rate of Prostacyclin and Prostacyclin Analogs (2018-2029)

    • Figure China Pulmonary Hypertension Drug Production Volume, Production Value and Growth Rate of Soluble Guanylate Cyclase Stimulators (2018-2029)

    • Figure China Pulmonary Hypertension Drug Sales Volume, Sales Value and Growth Rate of Early-stage Drug Candidates (Phase I & Phase II) (2018-2029)

    • Figure China Pulmonary Hypertension Drug Sales Volume, Sales Value and Growth Rate of Late-stage Drug Candidates (Phase III & Registration Phase) (2018-2029)

    • Figure North China Pulmonary Hypertension Drug Market Size and Growth Rate from 2018-2029

    • Figure Central China Pulmonary Hypertension Drug Market Size and Growth Rate from 2018-2029

    • Figure South China Pulmonary Hypertension Drug Market Size and Growth Rate from 2018-2029

    • Figure East China Pulmonary Hypertension Drug Market Size and Growth Rate from 2018-2029

    • Figure Northeast China Pulmonary Hypertension Drug Market Size and Growth Rate from 2018-2029

    • Figure Southwest China Pulmonary Hypertension Drug Market Size and Growth Rate from 2018-2029

    • Figure Northwest China Pulmonary Hypertension Drug Market Size and Growth Rate from 2018-2029

    • Figure Pulmonary Hypertension Drug Industry Chain

    • Table Product Types of Major Suppliers in 2023

    • Figure China Pulmonary Hypertension Drug Market Share by Type in 2018

    • Figure China Pulmonary Hypertension Drug Market Share by Type in 2023

    • Figure China Pulmonary Hypertension Drug Total Production Volume and Growth Rate from Production Side (2018-2023)

    • Figure China Pulmonary Hypertension Drug Production Volume and Growth Rate of Endothelin Receptor Antagonists (2018-2023)

    • Figure China Pulmonary Hypertension Drug Production Volume and Growth Rate of Phosphodiesterase-5 Inhibitors (2018-2023)

    • Figure China Pulmonary Hypertension Drug Production Volume and Growth Rate of Prostacyclin and Prostacyclin Analogs (2018-2023)

    • Figure China Pulmonary Hypertension Drug Production Volume and Growth Rate of Soluble Guanylate Cyclase Stimulators (2018-2023)

    • Figure China Pulmonary Hypertension Drug Market Share by Application in 2018

    • Figure China Pulmonary Hypertension Drug Market Share by Application in 2023

    • Figure China Pulmonary Hypertension Drug Total Market Size and Growth Rate from Consumption End

    • Figure China Pulmonary Hypertension Drug Market Size and Growth Rate of Early-stage Drug Candidates (Phase I & Phase II) (2018-2023)

    • Figure China Pulmonary Hypertension Drug Market Size and Growth Rate of Late-stage Drug Candidates (Phase III & Registration Phase) (2018-2023)

    • Table China Pulmonary Hypertension Drug Production Volume by Region (2018-2023)

    • Table China Pulmonary Hypertension Drug Production Volume Share by Region (2018-2023)

    • Figure China Pulmonary Hypertension Drug Production Volume Share by Region (2018-2023)

    • Table China Pulmonary Hypertension Drug Production Value by Region (2018-2023)

    • Table China Pulmonary Hypertension Drug Production Value Share by Region (2018-2023)

    • Figure China Pulmonary Hypertension Drug Production Value Share by Region (2018-2023)

    • Table China Pulmonary Hypertension Drug Sales Volume by Region (2018-2023)

    • Table China Pulmonary Hypertension Drug Sales Volume Share by Region (2018-2023)

    • Figure China Pulmonary Hypertension Drug Sales Volume Share by Region (2018-2023)

    • Table China Pulmonary Hypertension Drug Sales Value by Region (2018-2023)

    • Table China Pulmonary Hypertension Drug Sales Value Share by Region (2018-2023)

    • Figure China Pulmonary Hypertension Drug Sales Value Share by Region (2018-2023)

    • Table North China Pulmonary Hypertension Drug Production Volume by Type (2018-2023)

    • Table North China Pulmonary Hypertension Drug Production Volume Share by Type (2018-2023)

    • Figure North China Pulmonary Hypertension Drug Production Volume Share by Type (2018-2023)

    • Table North China Pulmonary Hypertension Drug Sales Volume by Application (2018-2023)

    • Table North China Pulmonary Hypertension Drug Sales Volume Share by Application (2018-2023)

    • Figure North China Pulmonary Hypertension Drug Sales Volume Share by Application (2018-2023)

    • Table Central China Pulmonary Hypertension Drug Production Volume by Type (2018-2023)

    • Table Central China Pulmonary Hypertension Drug Production Volume Share by Type (2018-2023)

    • Figure Central China Pulmonary Hypertension Drug Production Volume Share by Type (2018-2023)

    • Table Central China Pulmonary Hypertension Drug Sales Volume by Application (2018-2023)

    • Table Central China Pulmonary Hypertension Drug Sales Volume Share by Application (2018-2023)

    • Figure Central China Pulmonary Hypertension Drug Sales Volume Share by Application (2018-2023)

    • Table South China Pulmonary Hypertension Drug Production Volume by Type (2018-2023)

    • Table South China Pulmonary Hypertension Drug Production Volume Share by Type (2018-2023)

    • Figure South China Pulmonary Hypertension Drug Production Volume Share by Type (2018-2023)

    • Table South China Pulmonary Hypertension Drug Sales Volume by Application (2018-2023)

    • Table South China Pulmonary Hypertension Drug Sales Volume Share by Application (2018-2023)

    • Figure South China Pulmonary Hypertension Drug Sales Volume Share by Application (2018-2023)

    • Table East China Pulmonary Hypertension Drug Production Volume by Type (2018-2023)

    • Table East China Pulmonary Hypertension Drug Production Volume Share by Type (2018-2023)

    • Figure East China Pulmonary Hypertension Drug Production Volume Share by Type (2018-2023)

    • Table East China Pulmonary Hypertension Drug Sales Volume by Application (2018-2023)

    • Table East China Pulmonary Hypertension Drug Sales Volume Share by Application (2018-2023)

    • Figure East China Pulmonary Hypertension Drug Sales Volume Share by Application (2018-2023)

    • Table Northeast China Pulmonary Hypertension Drug Production Volume by Type (2018-2023)

    • Table Northeast China Pulmonary Hypertension Drug Production Volume Share by Type (2018-2023)

    • Figure Northeast China Pulmonary Hypertension Drug Production Volume Share by Type (2018-2023)

    • Table Northeast China Pulmonary Hypertension Drug Sales Volume by Application (2018-2023)

    • Table Northeast China Pulmonary Hypertension Drug Sales Volume Share by Application (2018-2023)

    • Figure Northeast China Pulmonary Hypertension Drug Sales Volume Share by Application (2018-2023)

    • Table Southwest China Pulmonary Hypertension Drug Production Volume by Type (2018-2023)

    • Table Southwest China Pulmonary Hypertension Drug Production Volume Share by Type (2018-2023)

    • Figure Southwest China Pulmonary Hypertension Drug Production Volume Share by Type (2018-2023)

    • Table Southwest China Pulmonary Hypertension Drug Sales Volume by Application (2018-2023)

    • Table Southwest China Pulmonary Hypertension Drug Sales Volume Share by Application (2018-2023)

    • Figure Southwest China Pulmonary Hypertension Drug Sales Volume Share by Application (2018-2023)

    • Table Northwest China Pulmonary Hypertension Drug Production Volume by Type (2018-2023)

    • Table Northwest China Pulmonary Hypertension Drug Production Volume Share by Type (2018-2023)

    • Figure Northwest China Pulmonary Hypertension Drug Production Volume Share by Type (2018-2023)

    • Table Northwest China Pulmonary Hypertension Drug Sales Volume by Application (2018-2023)

    • Table Northwest China Pulmonary Hypertension Drug Sales Volume Share by Application (2018-2023)

    • Figure Northwest China Pulmonary Hypertension Drug Sales Volume Share by Application (2018-2023)

    • Table Boehringer Ingelheim GmbH Company Profile

    • Table Boehringer Ingelheim GmbH Pulmonary Hypertension Drug Revenue, Price and Gross (2018-2023)

    • Table Merck & Co, Inc Company Profile

    • Table Merck & Co, Inc Pulmonary Hypertension Drug Revenue, Price and Gross (2018-2023)

    • Table GlaxoSmithKline plc Company Profile

    • Table GlaxoSmithKline plc Pulmonary Hypertension Drug Revenue, Price and Gross (2018-2023)

    • Table Teva Pharmaceutical Industries Ltd Company Profile

    • Table Teva Pharmaceutical Industries Ltd Pulmonary Hypertension Drug Revenue, Price and Gross (2018-2023)

    • Table AstraZeneca plc Company Profile

    • Table AstraZeneca plc Pulmonary Hypertension Drug Revenue, Price and Gross (2018-2023)

    • Table Vectura Group plc Company Profile

    • Table Vectura Group plc Pulmonary Hypertension Drug Revenue, Price and Gross (2018-2023)

    • Table Pfizer Inc Company Profile

    • Table Pfizer Inc Pulmonary Hypertension Drug Revenue, Price and Gross (2018-2023)

    • Table F Hoffmann-La Roche AG Company Profile

    • Table F Hoffmann-La Roche AG Pulmonary Hypertension Drug Revenue, Price and Gross (2018-2023)

    • Table Abbott Laboratories Company Profile

    • Table Abbott Laboratories Pulmonary Hypertension Drug Revenue, Price and Gross (2018-2023)


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US